XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Sep 30, 2024 | (FY)Sep 30, 2023 | (FY)Sep 30, 2022 | (FY)Sep 30, 2021 | (FY)Sep 30, 2020 | |
---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | |||||
Cash flow from continuing operating activities | -138.87%-1.21M | 96.53%3.11M | -72.95%1.58M | 133.43%5.84M | 2.5M |
Net income from continuing operations | 18.82%3.42M | 6.34%2.88M | 2.84%2.71M | 19.30%2.63M | --2.21M |
Operating gains losses | -518.64%-42.41K | ---6.86K | ---- | 3,741.09%13.37K | --348 |
Depreciation and amortization | 53.22%346.13K | -37.70%225.9K | 4.61%362.6K | 5.06%346.61K | --329.91K |
Deferred tax | -59.46%36.33K | 204.16%89.6K | -5,072.76%-86.02K | 97.87%-1.66K | ---77.92K |
Change In working capital | -2,349.91%-4.92M | 85.97%-200.81K | -148.33%-1.43M | 8,597.76%2.96M | ---34.86K |
-Change in receivables | -939.01%-3.91M | -212.71%-376.08K | -89.16%333.66K | 173.60%3.08M | --1.12M |
-Change in inventory | -94.84%80.32K | 408.38%1.56M | -209.98%-504.39K | 133.45%458.61K | ---1.37M |
-Change in prepaid assets | -90.22%-1.36M | -266.31%-716.36K | 154.36%430.74K | -4,642.58%-792.44K | ---16.71K |
-Change in payables and accrued expense | 161.06%417.66K | 26.92%-684.07K | -117.80%-936.03K | -233.18%-429.77K | --322.7K |
-Change in other current liabilities | ---83.73K | --0 | --0 | ---- | ---- |
-Change in other working capital | -414.77%-63.76K | 102.68%20.26K | -216.60%-755.37K | 785.46%647.86K | ---94.51K |
Cash from discontinued investing activities | |||||
Operating cash flow | -138.87%-1.21M | 96.53%3.11M | -72.95%1.58M | 133.43%5.84M | --2.5M |
Investing cash flow | |||||
Cash flow from continuing investing activities | -23.08%-9.51M | -6,293.71%-7.73M | 88.68%-120.9K | 45.49%-1.07M | -1.96M |
Net PPE purchase and sale | -39.31%-144.6K | -158.43%-103.8K | 6.33%-40.17K | 69.83%-42.88K | ---142.11K |
Net intangibles purchase and sale | ---979.28K | --0 | --0 | ---- | ---- |
Net investment purchase and sale | -10.01%-8.39M | -1,613.17%-7.63M | 45.02%-445.17K | -383.72%-809.73K | --285.4K |
Net other investing changes | ---- | ---- | 269.48%364.43K | 89.77%-215.03K | ---2.1M |
Cash from discontinued investing activities | |||||
Investing cash flow | -23.08%-9.51M | -6,293.71%-7.73M | 88.68%-120.9K | 45.49%-1.07M | ---1.96M |
Financing cash flow | |||||
Cash flow from continuing financing activities | 68.64%11.65M | 5,571.18%6.91M | 104.25%121.86K | -734.59%-2.87M | -343.91K |
Net issuance payments of debt | 61.42%6.87M | --4.25M | --0 | -678.54%-2.77M | ---355.32K |
Net common stock issuance | -96.10%312K | --8M | --0 | --0 | ---- |
Proceeds from stock option exercised by employees | --0 | --336.64K | --0 | --0 | ---- |
Net other financing activities | 178.80%4.48M | -4,761.29%-5.68M | 217.30%121.86K | -1,009.98%-103.88K | --11.42K |
Cash from discontinued financing activities | |||||
Financing cash flow | 68.64%11.65M | 5,571.18%6.91M | 104.25%121.86K | -734.59%-2.87M | ---343.91K |
Net cash flow | |||||
Beginning cash position | 44.59%6.93M | 30.51%4.79M | 120.75%3.67M | -14.34%1.66M | --1.94M |
Current changes in cash | -59.20%933.05K | 44.59%2.29M | -16.99%1.58M | 849.08%1.91M | --200.77K |
Effect of exchange rate changes | 282.54%273.63K | 67.50%-149.9K | -546.49%-461.24K | 121.56%103.3K | ---479.21K |
End cash Position | 17.41%8.14M | 44.59%6.93M | 30.51%4.79M | 120.75%3.67M | --1.66M |
Free cash flow | -177.91%-2.33M | 94.25%2.99M | -73.44%1.54M | 145.69%5.8M | --2.36M |
Currency Unit | USD | USD | USD | USD | USD |
Audit Opinions | Unqualified Opinion with Explanatory Notes | Unqualified Opinion | Unqualified Opinion | -- | -- |